1715 results for Treatments
Refine Your Search
TCR-like CARs targeting GvL mHAgs for the treatment of post-transplant AML relapse
AML recurrence is a devastating event after allo-HCT. I hypothesize that it could be counteracted through targeting of leukemia-restricted mHAgs via T…
FDA Approves First CAR T-Immunotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia
The U.S. Food and Drug Administration (FDA) recently announced approval of brexucabtagene autoleucel (Tecartus®) as the first and only CAR T-cell trea…
BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Cutaneous T-cell Lymphoma
Lund, Sweden – April 29, 2025 – BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and deve…
News Release
Alaska Blood Cancers Support Group
This online support group for blood cancer patients in Alaska will address specific issues related to a blood cancer diagnosis and will provide an opp…
Shop Online and In-Store at Walgreens to Support LLS
The Leukemia & Lymphoma Society (LLS) and Walgreens are in your corner. Since 2019, Walgreens has helped to raise more than $30 million for LLS and S…
Suggested Reading - Having Children After Cancer:How to Make Informed Choices before and After Treatment and Build the Family of Your Dreams
Having Children After Cancer: How to Make Informed Choices Before and After Treatment and Build the Family of Your Dreams by Gina M. ShawCelestial Art…
Secura Bio Announces the Presentation of New COPIKTRA® (duvelisib) Data for the Treatment of Patients with Relapsed or Refractory PTCL
SUMMERLIN, Nev., Dec. 14, 2021 - Secura Bio, Inc., an integrated pharmaceutical company dedicated to the worldwide development and commercialization o…
Healing Happens Around The Dinner Table
Too many parents lose their children to blood cancer each year. It’s a devastating experience for families blindsided by the harsh realities of cancer…
Evaluating a novel collaboration between NOTCH1 and MLL1 for improved targeted treatments in T-ALL
Most T cell acute lymphoblastic leukemia (T-ALL) patients respond to chemotherapy, however many relapse with limited therapy options. To address this …
Merging immune and molecular signals in HCL for improved prognosis and treatment decision making
Our research consortium of diagnostic, translational and clinical researchers will undertake an integrated and novel exploration of the immune and gen…
Sutro Biopharma Presents Data for STRO-001 for the Treatment of NHL and AML at ASH
SOUTH SAN FRANCISCO, Calif., Dec. 7, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing compa…
Interrogating T-cell apoptotic priming to improve CAR-T persistence in treatment of lymphoid malignancies
CAR-T cells are made from a patient’s own immune cells, altered so that they specifically recognize and kill the patient’s cancer cells. They are effe…
Creating Safe and Effective Cancer Treatments: FDA Approval Process for Cancer Drugs
By Abby Henry, Oncology Content Manager, PearlPoint Cancer Support
Pets and Cancer: How To Care for Yourself & Your Furry Friends During Treatment
For many people, pets feel like a part of the family. After a cancer diagnosis, pets can offer many benefits. Benefits include: companionship, improve…
Nearly 60% of Blood Cancer Patients Covered By Medicare Delay or Forgo Treatment
no-float col-12 View full multimedia release here. …
News Release
Blood Cancer 201: Moving Beyond the basics of Disease, Treatment and the Role of the HCP
This accredited CE activity is intended for social workers, nurses, and other healthcare professionals involved in the care of patients with hematolog…
Education Resources
Twin Cities All Blood Cancers Group
The group will address specific issues related to a blood cancer diagnosis and will provide an opportunity for attendees to discuss concerns, anxietie…
The History of Leukemia
Table of contentsHistory of LeukemiaFirst Studies of Blood and the Origin of LeukemiaEarly Leukemia DiscoveriesEarly Leukemia ClassificationEarly Leuk…
The Leukemia & Lymphoma Society's New Chief Scientific Officer Excited about What's Next in Blood Cancer Research
Lore Gruenbaum, Ph.D., was promoted to The Leukemia & Lymphoma Society’s (LLS) Chief Scientific Officer (CSO) following the retirement of longtime CSO…
Lansing Support Group - All Blood Cancers
The group will address specific issues related to a blood cancer diagnosis and will provide an opportunity for attendees to discuss concerns, anxietie…
Rhode Island Blood Cancer Support Group
The group will address specific issues related to a blood cancer diagnosis and will provide an opportunity for attendees to discuss concerns, anxietie…